Data gathered: December 26
Alternative Data for Citius Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 72 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 22,005 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. The company is headquartered in Cranford, New Jersey.
| Price | $3.14 |
| Target Price | Sign up |
| Volume | 23,990 |
| Market Cap | $87M |
| Year Range | $2.57 - $25.5 |
| Dividend Yield | 0% |
| Analyst Rating | 67% buy |
| Industry | Auto Parts |
In the news
 |
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Rule 5550(a)(2)December 22 - ETF Daily News |
|
Citius Pharmaceuticals (NASDAQ: CTXR) Holds Constructive FDA Type C Meeting Regarding Mino-Lok Program and Pathway to ApprovalNovember 26 - ETF Daily News |
 |
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalNovember 24 - Yahoo |
|
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock SplitNovember 21 - Yahoo |
 |
Citius Pharmaceuticals stock hits 52-week low at $0.16November 21 - Investing.com |
|
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of OfferingNovember 20 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 0 | 4.8M | -4.8M | -11M | -11M | -0.060 |
| Q1 '24 | 2.4M | 4.3M | -1.9M | -8.5M | -11M | -0.050 |
| Q4 '23 | 0 | 3.8M | -3.8M | -9.2M | -9.3M | -0.060 |
| Q3 '23 | 0 | 4.2M | -7.8M | -9.9M | -10M | -0.080 |
| Q2 '23 | 0 | 3.7M | -3.7M | -8.5M | -8.6M | -0.060 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Citius Pharmaceuticals (CTXR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Citius Pharmaceuticals?
The Market Cap of Citius Pharmaceuticals is $87M.
What is the current stock price of Citius Pharmaceuticals?
Currently, the price of one share of Citius Pharmaceuticals stock is $3.14.
How can I analyze the CTXR stock price chart for investment decisions?
The CTXR stock price chart above provides a comprehensive visual representation of Citius Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Citius Pharmaceuticals shares. Our platform offers an up-to-date CTXR stock price chart, along with technical data analysis and alternative data insights.
Does CTXR offer dividends to its shareholders?
As of our latest update, Citius Pharmaceuticals (CTXR) does not offer dividends to its shareholders. Investors interested in Citius Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Citius Pharmaceuticals?
Some of the similar stocks of Citius Pharmaceuticals are Gentex Corporation, AutoZone, Genuine Parts Company, Standard Motor Products, and Advance Auto Parts.
.